Train for Strength, Not for Size: A Dual-Pathway Framework Linking Growth Signalling, Cardiovascular Load, and the Case Against Extreme Hypertrophy

Background: Contemporary fitness culture and clinical geriatrics increasingly treat muscle massas an unconditional health good. However, converging evidence from molecular biology andcardiovascular physiology suggests that the pursuit of extreme hypertrophy may conflict withlongevity at a fundamental mechanistic level.Framework: We propose a dual-pathway convergence model. The first pathway is molecular: theGH/IGF-1/mTOR signalling cascade that drives muscle hypertrophy is the same pathway whosesuppression extends lifespan across all model organisms. Skeletal muscle hypertrophy requiressustained mTORC1 activation — placing it in direct mechanistic conflict with the mTORC1suppression associated with longevity. The second pathway is cardiovascular: larger, moremuscular bodies impose greater haemodynamic demand on a heart whose capacity declinesirreversibly with age, theoretically advancing the point at which cardiac output can no longer meettissue perfusion requirements.Evidence: Acromegaly (chronic GH excess) and Laron syndrome (GH receptor deficiency)constitute a natural dose–response experiment: growth signalling excess produces acceleratedcardiovascular deterioration and shortened lifespan; growth signalling absence producescardiovascular resilience and disease protection. Professional bodybuilders — who replicateacromegalic physiology through pharmacological and behavioural means — exhibit 34% excessmortality, with sudden cardiac death accounting for 38% of all fatalities. Critically,epidemiological evidence consistently shows that muscle strength, not muscle mass, predictssurvival — and the two are dissociable.Conclusion: The optimal target for health and longevity is neuromuscular efficiency — thecapacity to generate force per unit of metabolically active tissue — not maximal hypertrophy.Train for strength, not for size.